Ichiyo Shibahara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ichiyo Shibahara has a total of 222 co-authors. Here are the top co-authors by number of shared publications:
Toshihiro Kumabe
Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
24 shared publicationsMadoka Inukai
Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
13 shared publicationsTakuichiro Hide
Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
13 shared publicationsSumito Sato
Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
12 shared publications- Alexandra Rasnitsyn
The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada
11 shared publications - Ana Guerreiro Stucklin
Division of Oncology and Children’s Research Center, University Children’s Hospital of Zurich, Zurich, Switzerland
11 shared publications
Latest Publications
- 2 July 2026
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 152, 112174
Clinical utility of maximal and minimal intensity projections in T2-weighted MRI for neurosurgical planning
- 2 July 2026
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 152, 112174
Clinical utility of maximal and minimal intensity projections in T2-weighted MRI for neurosurgical planning
- Open Access
- 19 January 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 11 (3)
Recurrent pediatric posterior fossa anaplastic ependymoma managed with multiple resections: illustrative case
BACKGROUND: Maximal safe resection of ependymoma should be attempted whenever feasible. To clarify the potential and limits of surgery in recurrent pediatric ependymoma, the authors report a posterior fossa anaplastic ependymoma in a boy who ultimately underwent 18 resections. OBSERVATIONS: After initial multimodal therapy, resection with no detectable contrast-enhancing tumor on imaging and/or no visually apparent residual tumor intraoperatively was achieved at each operation from the 5th through the 16th, yielding 8 years 8 months of surgery-only local control. At the 17th surgery, a small remnant invading the right dorsolateral medulla was unavoidable; 7 months later, an 18th procedure achieved only partial resection and was followed by reirradiation. Recurrences arose from varying ependymal sites along the floor of the fourth ventricle rather than a single fixed locus, and a normal-appearing ependymal lining re-formed after sequential resections. Across all 18 operations, no infectious complications occurred. The tumor later progressed to circumferential brainstem involvement, and the patient died of respiratory failure 16 years 8 months after initial therapy. LESSONS: Repeated resections achieving no radiographic and intraoperative residual tumor may contribute to long-term survival in ependymoma; however, durable survival appears to depend on the persistence of locally resectable relapse. https://thejns.org/doi/10.3171/CASE25834
- 19 January 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 11 (3)
Open AccessRecurrent pediatric posterior fossa anaplastic ependymoma managed with multiple resections: illustrative case
BACKGROUND: Maximal safe resection of ependymoma should be attempted whenever feasible. To clarify the potential and limits of surgery in recurrent pediatric ependymoma, the authors report a posterior fossa anaplastic ependymoma in a boy who ultimately underwent 18 resections. OBSERVATIONS: After initial multimodal therapy, resection with no detectable contrast-enhancing tumor on imaging and/or no visually apparent residual tumor intraoperatively was achieved at each operation from the 5th through the 16th, yielding 8 years 8 months of surgery-only local control. At the 17th surgery, a small remnant invading the right dorsolateral medulla was unavoidable; 7 months later, an 18th procedure achieved only partial resection and was followed by reirradiation. Recurrences arose from varying ependymal sites along the floor of the fourth ventricle rather than a single fixed locus, and a normal-appearing ependymal lining re-formed after sequential resections. Across all 18 operations, no infectious complications occurred. The tumor later progressed to circumferential brainstem involvement, and the patient died of respiratory failure 16 years 8 months after initial therapy. LESSONS: Repeated resections achieving no radiographic and intraoperative residual tumor may contribute to long-term survival in ependymoma; however, durable survival appears to depend on the persistence of locally resectable relapse. https://thejns.org/doi/10.3171/CASE25834
- Open Access
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Role of antiseizure medication in postoperative late seizure and survival among patients with newly diagnosed glioblastoma: A multicenter retrospective study
Background: We conducted a multicenter study to investigate the utility of postoperative antiseizure medication (ASM) in the occurrence of late seizure in glioblastoma. In addition, we analyzed whether postoperative ASM affects survival. Methods: 1132 consecutive patients with newly diagnosed glioblastoma at 39 centers were enrolled. In patients treated with postoperative ASM (levetiracetam [LEV], lacosamide [LCM], or perampanel [PER]), as well as in those who received no medication, the cumulative incidence of late seizure, adverse events, and survival outcomes were analyzed. Results: In total, 1099 patients (female: 482, male: 617, mean age: 67.2 years) were included, among whom, 287 developed postoperative late seizure. The mean onset time of late seizure was 193.6 days after surgery. Postoperative ASMs were administered in 628 cases, LEV in 344, LCM in 124, and PER in 160. The cumulative incidence of late seizure at 12 months was as follows: no medication in 30.9%, LEV in 17.8%, LCM in 28.8%, and PER in 16.2%. Multivariable analysis disclosed that LEV and PER displayed significantly lower cumulative incidences of postoperative late seizure compared with no medication and LCM. By contrast, median progression-free survival/overall survival did not significantly differ among ASMs. However, during the 12–24 month interval, the PER group demonstrated a more favorable prognosis than the other groups. Conclusions: LEV and PER after glioblastoma surgery were associated with a reduced risk of late seizure compared with LCM or no medication. LEV or PER may be considered as postoperative ASMs to optimize seizure control and potentially help preserve patients’ QOL.
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Open AccessRole of antiseizure medication in postoperative late seizure and survival among patients with newly diagnosed glioblastoma: A multicenter retrospective study
Background: We conducted a multicenter study to investigate the utility of postoperative antiseizure medication (ASM) in the occurrence of late seizure in glioblastoma. In addition, we analyzed whether postoperative ASM affects survival. Methods: 1132 consecutive patients with newly diagnosed glioblastoma at 39 centers were enrolled. In patients treated with postoperative ASM (levetiracetam [LEV], lacosamide [LCM], or perampanel [PER]), as well as in those who received no medication, the cumulative incidence of late seizure, adverse events, and survival outcomes were analyzed. Results: In total, 1099 patients (female: 482, male: 617, mean age: 67.2 years) were included, among whom, 287 developed postoperative late seizure. The mean onset time of late seizure was 193.6 days after surgery. Postoperative ASMs were administered in 628 cases, LEV in 344, LCM in 124, and PER in 160. The cumulative incidence of late seizure at 12 months was as follows: no medication in 30.9%, LEV in 17.8%, LCM in 28.8%, and PER in 16.2%. Multivariable analysis disclosed that LEV and PER displayed significantly lower cumulative incidences of postoperative late seizure compared with no medication and LCM. By contrast, median progression-free survival/overall survival did not significantly differ among ASMs. However, during the 12–24 month interval, the PER group demonstrated a more favorable prognosis than the other groups. Conclusions: LEV and PER after glioblastoma surgery were associated with a reduced risk of late seizure compared with LCM or no medication. LEV or PER may be considered as postoperative ASMs to optimize seizure control and potentially help preserve patients’ QOL.
- Open Access
- 2 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Retrograde longitudinal imaging analyses of IDH -wildtype glioblastoma reveal its clinical timeline from radiological birth to death
Background: Glioblastoma (GB), IDH-wildtype, and low-grade glioma appear indistinguishable in their early pre-symptomatic phase, yet GB follows a far more aggressive clinical course. While genomic studies suggest a “biological birth” of GB years before diagnosis, when GB first becomes radiologically detectable (radiological birth) remains unknown. Methods: We analyzed longitudinal imaging data from 67 early-stage glioblastoma (earlyGB) cases, characterized by small, asymptomatic lesions that later progressed to classic magnetic resonance imaging appearance of GB (classicGB), comprising 44 institutional and 23 from published reports. A mathematical model integrating tumor volume, radius, imaging intervals, clinical data, and molecular features estimated radiological birth and its modifiers. Results: The median interval from earlyGB to classicGB was 155 days (range: 35-1557) in our cohort and 113 days (range: 4-854) in the published cohort. Radiological birth occurred 0.83 years (95% CI: 0.66-1.10) before diagnosis in our cohort and 0.15-0.92 years in the published cohort. Rapid progression correlated with age <65 years, MIB1 labeling index ≥30%, and copy-number alterations (CNAs) in EGFR, PTEN, or CDKN2A, but not with TERT promoter status. Absence of these CNAs prolonged the radiological birth to 2.27 years (95% CI: 0.79-100), indicating slower progression. Median overall survival of our cohort was 1.7 years, yielding a radiological-birth-to-death span of 2.8 years. Conclusions: This largest earlyGB cohort defines the radiological birth and entire clinical trajectory of IDH-wildtype GB. These findings bridge the gap between biological and radiological birth and offer a benchmark for surveillance and early-intervention strategies.
- 2 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Open AccessRetrograde longitudinal imaging analyses of IDH -wildtype glioblastoma reveal its clinical timeline from radiological birth to death
Background: Glioblastoma (GB), IDH-wildtype, and low-grade glioma appear indistinguishable in their early pre-symptomatic phase, yet GB follows a far more aggressive clinical course. While genomic studies suggest a “biological birth” of GB years before diagnosis, when GB first becomes radiologically detectable (radiological birth) remains unknown. Methods: We analyzed longitudinal imaging data from 67 early-stage glioblastoma (earlyGB) cases, characterized by small, asymptomatic lesions that later progressed to classic magnetic resonance imaging appearance of GB (classicGB), comprising 44 institutional and 23 from published reports. A mathematical model integrating tumor volume, radius, imaging intervals, clinical data, and molecular features estimated radiological birth and its modifiers. Results: The median interval from earlyGB to classicGB was 155 days (range: 35-1557) in our cohort and 113 days (range: 4-854) in the published cohort. Radiological birth occurred 0.83 years (95% CI: 0.66-1.10) before diagnosis in our cohort and 0.15-0.92 years in the published cohort. Rapid progression correlated with age <65 years, MIB1 labeling index ≥30%, and copy-number alterations (CNAs) in EGFR, PTEN, or CDKN2A, but not with TERT promoter status. Absence of these CNAs prolonged the radiological birth to 2.27 years (95% CI: 0.79-100), indicating slower progression. Median overall survival of our cohort was 1.7 years, yielding a radiological-birth-to-death span of 2.8 years. Conclusions: This largest earlyGB cohort defines the radiological birth and entire clinical trajectory of IDH-wildtype GB. These findings bridge the gap between biological and radiological birth and offer a benchmark for surveillance and early-intervention strategies.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy